Monte Rosa Therapeutics, Inc. (GLUE) Net Margin
- 2026-06-30: Net Margin -483.91%.
- 2026-03-31: Net Margin -1057.08%.
- 2025-12-31: Net Margin -1658.94%.
- 2025-09-30: Net Margin -212.10%.
Complete source-backed net margin history.
- Available history
- 2024-03-31 to 2026-06-30
- Data captured
Historical Net Margin
| Date | Net Margin |
|---|---|
| 2026-06-30 | -483.91% |
| 2026-03-31 | -1057.08% |
| 2025-12-31 | -1658.94% |
| 2025-09-30 | -212.10% |
| 2025-06-30 | -53.01% |
| 2025-03-31 | 55.20% |
| 2024-12-31 | 22.16% |
| 2024-09-30 | -258.89% |
| 2024-06-30 | -645.58% |
| 2024-03-31 | -3004.51% |
Annual Net Margin
| Date | Net Margin |
|---|---|
| 2025-12-31 | -31.23% |
| 2024-12-31 | -96.14% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |